Payment overview · 2025
General Payments
$4,993.10
247 reported records · 44 companies
Healthcare provider profile · identity verified
Arnaldo Isa, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · MAITLAND, FL · NPI 1952390452
Verified facts
What the public records show
CMS Open Payments records show Arnaldo Isa, M.D. received $4,993.10 in general payments during 2025 across 247 reported records.
Neurocrine BioSciences, Inc. accounted for 14.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 47 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gamunex-C, Gocovri, Ingrezza, Nurtec Odt, Qulipta, Rexulti, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Ubrelvy by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ONGENTYS as an associated drug or biological on 728 records involving 311 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ongentys by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Rytary by this doctor in 2024.
Grifols USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gamunex-C as an associated drug or biological on 3977 records involving 2134 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Gamunex-C by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rexulti by this doctor in 2024.
MDD US Operations, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gocovri as an associated drug or biological on 3202 records involving 1029 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Gocovri by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Ingrezza by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Nurtec Odt by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Xcopri by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GAMMAGARD LIQUID as an associated drug or biological on 29 records involving 8 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Gammagard Liquid by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $699.19 | 14.0% | 37 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $446.47 | 8.9% | 25 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $371.69 | 7.4% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $358.66 | 7.2% | 19 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $319.01 | 6.4% | 16 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $288.33 | 5.8% | 42 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $276.53 | 5.5% | 10 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $165.13 | 3.3% | 7 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $149.00 | 3.0% | 7 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $146.27 | 2.9% | 6 | 2025 |
| BIOTRONIK INC. | Unresolved — no canonical attribution shown | $140.39 | 2.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $103.52 | 2.1% | 4 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $99.31 | 2.0% | 4 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $99.17 | 2.0% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $90.92 | 1.8% | 4 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $78.37 | 1.6% | 4 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $77.54 | 1.6% | 3 | 2025 |
| Janssen Scientific Affairs, LLC | Unresolved — no canonical attribution shown | $75.90 | 1.5% | 1 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $74.23 | 1.5% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $74.17 | 1.5% | 4 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $65.06 | 1.3% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $63.15 | 1.3% | 3 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $55.15 | 1.1% | 2 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $53.25 | 1.1% | 2 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $52.02 | 1.0% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $49.33 | 1.0% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $45.51 | 0.9% | 2 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $44.61 | 0.9% | 2 | 2025 |
| Tanabe Pharma America, Inc. | Unresolved — no canonical attribution shown | $43.34 | 0.9% | 2 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $40.54 | 0.8% | 2 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$40.02 | 0.8% | 2 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $37.46 | 0.8% | 1 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$33.53 | 0.7% | 1 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $30.55 | 0.6% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $29.96 | 0.6% | 1 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $25.24 | 0.5% | 1 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $24.95 | 0.5% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.42 | 0.5% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $21.71 | 0.4% | 1 | 2025 |
| REVANCE THERAPEUTICS, INC. | Unresolved — no canonical attribution shown | $18.11 | 0.4% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $17.90 | 0.4% | 1 | 2025 |
| Impel Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $15.31 | 0.3% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $15.20 | 0.3% | 1 | 2025 |
| C2N Diagnostics, LLC | Unresolved — no canonical attribution shown | $14.98 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,975.20 | 246 |
| Education | $17.90 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $699.19 | 37 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $387.45 | 22 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $387.45 | 22 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $371.69 | 9 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $328.23 | 16 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $288.33 | 42 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $280.64 | 14 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $155.25 | 8 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $145.40 | 7 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $142.38 | 4 | 2025 |
Source payment records
|
|||||
| BIOMONITOR Normalized: biomonitor |
Device | BIOTRONIK INC. | $140.39 | 1 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $134.15 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $133.39 | 6 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $130.31 | 7 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $103.52 | 4 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $99.31 | 4 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $99.17 | 3 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $90.92 | 4 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $78.37 | 4 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $77.54 | 3 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $77.25 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $74.17 | 4 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $63.15 | 3 | 2025 |
Source payment records
|
|||||
| SPINRAZA Normalized: spinraza |
Biological | Biogen, Inc. | $59.89 | 3 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $55.15 | 2 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $53.25 | 2 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $52.02 | 3 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $49.33 | 2 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $44.61 | 2 | 2025 |
Source payment records
|
|||||
| Radicava Normalized: radicava |
Drug | Tanabe Pharma America, Inc. | $43.34 | 2 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $43.16 | 2 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $40.02 | 2 | 2025 |
Source payment records
|
|||||
| FIRDAPSE Normalized: firdapse |
Drug | CATALYST PHARMACEUTICALS, INC. | $37.46 | 1 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $30.55 | 1 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $30.43 | 3 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $29.96 | 1 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $25.24 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $24.95 | 1 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $23.53 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $22.42 | 1 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $21.71 | 1 | 2025 |
Source payment records
|
|||||
| AVONEX Normalized: avonex |
Biological | Biogen, Inc. | $19.17 | 1 | 2025 |
Source payment records
|
|||||
| DAXXIFY Normalized: daxxify |
Drug | REVANCE THERAPEUTICS, INC. | $18.11 | 1 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $15.86 | 1 | 2025 |
Source payment records
|
|||||
| TRUDHESA Normalized: trudhesa |
Drug | Impel Pharmaceuticals LLC | $15.31 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $15.20 | 1 | 2025 |
Source payment records
|
|||||
| PRECIVITYAD2 Normalized: precivityad2 |
Device | C2N Diagnostics, LLC | $14.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Gamunex-C gamunex c |
2025 | Gamunex-C | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Gocovri gocovri |
2025 | Gocovri | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 31 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 33 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
33 | 16 |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | ONGENTYS open payments reported associated product |
CMS Open Payments — General Payments 728 supporting records · 311 recipient NPIs · example record 1220525547 |
Ongentys · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Grifols USA, LLC Exact reporting entity; no affiliate inference |
2025 | Gamunex-C open payments reported associated product |
CMS Open Payments — General Payments 3977 supporting records · 2134 recipient NPIs · example record 1249529381 |
Gamunex-C · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| MDD US Operations, LLC Exact reporting entity; no affiliate inference |
2025 | Gocovri open payments reported associated product |
CMS Open Payments — General Payments 3202 supporting records · 1029 recipient NPIs · example record 1241843637 |
Gocovri · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
31 | 11 |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | GAMMAGARD LIQUID open payments reported associated product |
CMS Open Payments — General Payments 29 supporting records · 8 recipient NPIs · example record 1223786557 |
Gammagard Liquid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Donepezil Hcl | Donepezil Hcl | 830 | 233 |
| Gabapentin | Gabapentin | 657 | 186 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 568 | 156 |
| Memantine Hcl | Memantine Hcl | 568 | 141 |
| Levetiracetam | Levetiracetam | 287 | 73 |
| Buspirone Hcl | Buspirone Hcl | 220 | 56 |
| Galantamine Er | Galantamine Hbr | 208 | 52 |
| Pregabalin | Pregabalin | 190 | 49 |
| Rivastigmine | Rivastigmine Tartrate | 186 | 45 |
| Lamotrigine | Lamotrigine | 159 | 35 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 158 | 44 |
| Clonazepam | Clonazepam | 153 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 150 | 44 |
| Topiramate | Topiramate | 129 | 33 |
| Sertraline Hcl | Sertraline Hcl | 128 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 126 | 38 |
| Prednisone | Prednisone | 114 | 47 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 113 | 28 |
| Baclofen | Baclofen | 107 | 27 |
| Primidone | Primidone | 99 | 33 |
| Mirtazapine | Mirtazapine | 98 | 32 |
| Quetiapine Fumarate | Quetiapine Fumarate | 84 | 18 |
| Alprazolam | Alprazolam | 83 | 25 |
| Emgality Pen | Galcanezumab-Gnlm | 80 | 14 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 73 | 16 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 65 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 62 | 18 |
| Rivastigmine | Rivastigmine | 59 | 15 |
| Levetiracetam Er | Levetiracetam | 46 | 11 |
| Diazepam | Diazepam | 45 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 45 | suppressed |
| Rytary | Carbidopa/Levodopa | 45 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 44 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 43 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 41 | 14 |
| Memantine Hcl Er | Memantine Hcl | 40 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 38 | suppressed |
| Clobazam | Clobazam | 36 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 36 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 36 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 35 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 35 | 11 |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 34 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 34 | 14 |
| Lorazepam | Lorazepam | 33 | 16 |
| Ubrelvy | Ubrogepant | 33 | 16 |
| Lacosamide | Lacosamide | 32 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 32 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Entacapone | Entacapone | 31 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 31 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 31 | suppressed |
| Dalfampridine Er | Dalfampridine | 29 | suppressed |
| Risperidone | Risperidone | 29 | suppressed |
| Neupro | Rotigotine | 27 | suppressed |
| Amantadine | Amantadine Hcl | 26 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 26 | suppressed |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 25 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 25 | suppressed |
| Vimpat | Lacosamide | 25 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Gocovri | Amantadine Hcl | 22 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Lamictal | Lamotrigine | 20 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 19 | suppressed |
| Meloxicam | Meloxicam | 19 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Carbamazepine | Carbamazepine | 18 | suppressed |
| Ingrezza | Valbenazine Tosylate | 18 | suppressed |
| Qulipta | Atogepant | 18 | suppressed |
| Modafinil | Modafinil | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | 11 |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Emgality Syringe | Galcanezumab-Gnlm | 15 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 14 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 14 | suppressed |
| Carbamazepine Er | Carbamazepine | 14 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Neurontin | Gabapentin | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Rexulti | Brexpiprazole | 14 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 14 | suppressed |
| Xcopri | Cenobamate | 14 | suppressed |
| Zonisamide | Zonisamide | 14 | suppressed |
| Copaxone | Glatiramer Acetate | 13 | suppressed |
| Kesimpta Pen | Ofatumumab | 13 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Ongentys | Opicapone | 12 | suppressed |
| Tegretol Xr | Carbamazepine | 12 | suppressed |
| Acetazolamide | Acetazolamide | 11 | suppressed |
| Austedo | Deutetrabenazine | 11 | suppressed |
| Glatiramer Acetate | Glatiramer Acetate | 11 | suppressed |
| Rebif | Interferon Beta-1a/Albumin | 11 | suppressed |
| Topamax | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,993.10 · 247 records | Neurocrine BioSciences, Inc. | ACTHAR, AUSTEDO XR, AVONEX, BIOMONITOR, BOTOX, BRIUMVI, CREXONT, DAXXIFY, FIRDAPSE, Gamunex-C, Gocovri, HYQVIA, INGREZZA, INSPIRE, KESIMPTA, KEVEYIS, KISUNLA, LEQEMBI, NURTEC ODT, Nayzilam, Ocrevus Zunovo, PANZYGA, PONVORY, PRECIVITYAD2, QULIPTA, Qelbree, REXULTI, Radicava, Rystiggo, SKYCLARYS, SPINRAZA, Senza, Sunosi, TRUDHESA, TYSABRI, UBRELVY, ULTOMIRIS, UPLIZNA, VALTOCO, VUMERITY, VYALEV, VYEPTI, VYVGART HYTRULO, XYWAV, Xeomin, ZAVZPRET, ZEPOSIA | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gamunex-C play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error